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Stroke remains to be the leading cause of mortality in China and was responsible for ≈1.9 million deaths in 2013.1 
Despite advances in diagnosis and treatments for stroke, 
adherence to evidence-based stroke care has been suboptimal 
based on several national studies conducted before 2009.2,3 
Since then, improving the quality of stroke care has become 
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a national priority.4 This interest has led to several quality 
management initiatives by the China Ministry of Health after 
2008 to promote adherence to guideline-recommended per-
formance measures for acute ischemic stroke.4–8
We sought to assess the change in the quality of acute isch-
emic stroke care by comparing the adherence to guideline-rec-
ommended performance measures before 2009 with that after 
the implementation of these initiatives since 2009.
Methods
China National Stroke Registries
The China National Stroke Registry (CNSR) is a national hospital-
based, prospective stroke registry.9 Data collected among 131 hospitals 
during September 2007 to August 2008 were used as CNSR phase 1 or 
the baseline for the current study. CNSR phase 2 was launched during 
June 2012 to January 2013 and consisted of 219 hospitals. Among 
them, 72 hospitals participated in both CNSR phase 1 and 2, 59 sites 
only in CNSR phase 1 and 147 hospitals only in phase 2. These 147 
hospitals were selected by a Steering Committee using a convenient 
sampling method from the China National Network of Stroke Research 
developed by the National Center of Quality Management in Stroke 
Care including 491 hospitals and matched based on the comparability 
of the data from the 2007 to 2008 data, including geographic region, 
teaching status, hospital beds, and annual stroke discharges. The flow 
chart of the study is shown in Figure 1. The study was approved by the 
Institutional Review Board of the Beijing Tiantan Hospital.
Case Identification and Data Abstraction
Trained research co-ordinators at each site examined all medical 
records of stroke patients to identify eligible cases for the registries. 
Adult inpatients (≥18 years of age) with acute ischemic stroke at 
admission as evidenced by brain computed tomography or magnetic 
resonance imaging were included. Informed consent was obtained 
from patients or legal representatives. All subjects received an eval-
uation using the National Institutes of Health Stroke Scale within 24 
hours of hospital admission. The following variables are extracted 
from medical documents: patient demographics, onset-to-door 
time, health insurance schemes10 (urban basic medical insurance 
schemes for urban and governmental employees and urban resi-
dents, new rural cooperative medical schemes for rural residents, 
commercial insurance, and self-payment), vascular risk factors, and 
implementation of performance measures for acute stroke care, final 
diagnosis, length of stay, modified Rankin scale at discharge, and 
in-hospital death. Hospital-level information included geographic 
region (eastern, central, and western areas according to the annual 
report on health statistics of China11), teaching status, hospital bed 
size, and annual stroke volume. The definitions of the variables 
were described in the Table I in the online-only Data Supplement.
Quality Measures for Stroke Care and Prevention
A total of 13 guideline-recommended performance metrics were 
prespecified for this study by the Steering Committee based on the 
national standards, guidelines’ recommendations,6–8 and Get With 
The Guidelines-Stroke (GWTG-Stroke),12 including 6 acute perfor-
mance measures: (1) intravenous tissue-type plasminogen activator 
(tPA) in patients who arrive within 2 hours after symptom onset and 
treated within 3 hours, (2) antithrombotic medication within 48 hours 
of admission, (3) deep vein thrombosis prophylaxis within 48 hours 
of admission for nonambulatory patients, (4) dysphagia screening 
before any oral intake, (5) carotid imaging, (6) assessment or receiv-
ing of rehabilitation and 7 performance measures at discharge: (1) 
antithrombotic medication, (2) anticoagulation for atrial fibrillation, 
(3) antihypertensive medication for patients with hypertension, (4) 
medications for lowering low-density lipoprotein ≥100 mg/dL, (5) 
hypoglycemia medication for diabetes mellitus, (6) smoking ces-
sation, and (7) stroke education (Table Ⅱ in the online-only Data 
Supplement).
A composite score was developed and defined as the total number of 
interventions actually performed among eligible patients divided by the 
total number of recommended interventions among eligible patients.12
Statistical Analyses
Both patient and hospital characteristics were reported as median 
with interquartile ranges for continuous variable and as frequency 
and percentage for categorical variables by 2 study period, CNSR 
phase 1 (2007–2008) and phase 2 (2012–2013). The differences are 
tested by χ2 tests for categorical variables and Wilcoxon rank-sum test 
for continuous variables.
The primary outcomes were the difference in adherence to the 
guideline-based performance measures between the 2 study periods, 
as reflected, respectively, by 13 individual measures, the composite 
score, and the odds of fulfilling care opportunities for eligible perfor-
mance measures as described in previous research.13 As for the odds 
of fulfilling care opportunities, each measure for which a patient was 
eligible contributed an observation in the analysis, and the outcome 
was a dichotomized (1: measure met versus 0: measure not met).13 
For example, if a particular patient was eligible for 6 of the 8 per-
formance measures and only received 3 of them, this patient contrib-
uted 6 observations to the analysis. Multiple regression models were 
developed to evaluate the difference in adherence to performance 
measure between the 2 study periods. These analyses adjusted for 
patient and hospital characteristics, including age, race, sex, insur-
ance schemes, previous stroke/transient ischemic attack, diabetes 
mellitus, hypertension, dyslipidemia, coronary heart disease/previous 
myocardial infarction, atrial fibrillation, ever smoking, stroke sever-
ity, hospital geographic region, teaching status, number of hospital 
beds, and annual stroke discharges. Generalized estimating equations 
were used to account for within-hospital clustering.
Figure 1. Flow chart of hospitals and 
patients enrollment among Stroke Care 
Quality Registries. IS indicates ischemic 
stroke.
D
ow
nloaded from
 http://ahajournals.org by on August 16, 2019
Li et al  Improvement in Stroke Care in China   2845
The primary analysis included all hospitals in the CNSR phase 1 
and 2. A sensitivity analysis was performed in 72 hospitals partici-
pated in both CNSR phase 1 and 2.
All tests are 2-tailed with P<0.05 regarded as the level of statistical 
significance. All statistical analyses were performed using SAS ver-
sion 9.3 (SAS Institute, Cary, NC).
Results
Hospital and Patient Characteristics: 
2007 to 2008 Versus 2012 to 2013
A total of 278 hospitals were included, among which 72 
(25.9%) hospitals participated in both time periods. Proportion 
of teaching hospitals, regional representation, average hospi-
tal bed size, and annual stroke discharge volume were similar 
between 2007 to 2008 and 2012 to 2013 (P>0.05; Table Ⅲ in 
the online-only Data Supplement).
A total of 31 777 subjects were included in the analysis: 
12 173 from the 131 hospitals in the 2007 to 2008 data set and 
19 604 patients from the 219 hospitals in the 2012 to 2013 data 
set. Patient demographics, medical insurance types, and vascular 
risk factors are compared in Table 1. Because of large sample 
size, many of the difference are statistically significant but may 
not be clinically meaningful. Generally, patients in the 2012 
to 2013 data set were slightly younger (median 65 versus 67), 
were more likely to have new rural cooperative medical schemes 
insurance (39.5% versus 16.8%), and had less severe stroke 
(National Institutes of Health Stroke Scale; median 4 versus 
5). Similar trend of characteristics above was also observed in 
patients admitted to 72 hospitals that participated in both CNSR 
phase 1 and 2 (Table Ⅳ in the online-only Data Supplement). 
As for stroke-related in-hospital outcomes, patients in the 2012 
to 2013 data set had a shorter length of stay, better functional 
outcome at discharge (modified Rankin scale ≤2), and a lower 
rate of the in-hospital death (all P<0.001; Table 1).
Adherence to Performance Measures: 
2007 to 2008 Versus 2012 to 2013
Adherence to each individual performance measure 
and the composite measure during the 2 study periods 
Table 1. Patient Characteristics Between 2 Phases of Stroke Care Quality Registries 
(2007 to 2008 and 2012 to 2013)
 
 Level
All Participating Hospitals
P Value2007–2008, n (%) 2012–2013, n (%)
Demographics
 Age, y Median (IQR) 67 (57–75) 65 (57–74) <0.001
 Race Han 11 799 (96.9) 18 980 (96.8) 0.596
 Non-Han 374 (3.1) 624 (3.2)  
 Sex Male 7513 (61.7) 12 437 (63.4) 0.002
 Female 4660 (38.3) 7167 (36.3)  
Insurance scheme UBMIS 7429 (61.0) 10 021 (51.1) <0.001
 NRCMS 2039 (16.8) 7747 (39.5)  
 Commercial 397 (3.3) 69 (0.4)  
 Self-payment 2308 (19.0) 1767 (9.0)  
Medical history
  Previous stroke/TIA Yes 4152 (34.1) 6979 (35.6) 0.007
  Diabetes mellitus Yes 2625 (21.6) 4060 (20.7) 0.069
  Hypertension Yes 7780 (63.9) 12 697 (64.8) 0.121
  Dyslipidemia Yes 1369 (11.2) 2370 (12.1) 0.023
  CHD/previous MI Yes 1764 (14.5) 2655 (13.5) 0.018
  Atrial fibrillation Yes 901 (7.4) 1382 (7.0) 0.237
  Ever smoking Yes 4845 (39.8) 8672 (44.2) <0.001
Onset-to-door time, h Median (IQR) 24.0 (9.0–72.0) 22.0 (5.5–53.5) <0.001
NIHSS at admission Median (IQR) 5 (2–9) 4 (2–7) <0.001
In-hospital outcomes
  Length of stay, d Median (IQR) 14 (11–20) 13 (9–16) <0.001
  mRS ≤2 at discharge Yes 8190 (67.3) 14 712 (75.0) <0.001
 In-hospital mortality Yes 496 (4.1) 222 (1.1) <0.001
CHD indicates coronary heart disease; IQR, interquartile range; MI, myocardial infarction; mRS, modified 
Rankin scale; NIHSS, National Institutes of Health Stroke Scale; NRCMS, new rural cooperative medical 
schemes; TIA, transient ischemic attack; and UBMIS, urban basic medical insurance schemes.
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are shown in Figure 2 and Table 2. The composite mea-
sure was increased from 0.63 in 2007 to 2008 to 0.76 in 
2012 to 2013 (P<0.001). After adjusting for patient and 
hospital characteristics, multilevel model by using gener-
alized estimated equations method analysis showed sig-
nificant improvements in the composite measure and all 
9 individual performance measures (Table 2). There was 
no statistically significant improvement in intravenous 
thrombolytics (18.3% versus 14.1%), early antithrombot-
ics (84.6% versus 80.3%), deep vein thrombosis prophy-
laxis (65.0% versus 59.6%), and anticoagulation for atrial 
fibrillation (21.0% versus 19.7%), either in the unadjusted 
or adjusted analysis (Table 2).
Overall, there was 1.17-fold increase in the odds of 
receiving each performance measure between 2007 to 2008 
and 2012 to 2013 after adjusting patients’ and hospitals’ 
characteristics. The top 4 performance metrics with the 
significantly increased odds included stroke education, 
dysphagia screening, smoking cessation, and antithrom-
botics at discharge. The increase in the odds of fulfilling 
care opportunities between 2007 to 2008 and 2012 to 2013 
was consistent across all subtypes of hospitals (P>0.05 
for all comparisons) except geographic region (Western 
versus Eastern: odds ratio=1.04; 95% confidence inter-
val, 1.00–1.08; P=0.038; Table Ⅴ in the online-only Data 
Supplement).
Sensitivity analysis of 72 hospitals participating in both phase 
1 and 2 also revealed substantial improvements in the compos-
ite measure. Nine of the 13 individual performance measures 
(except for intravenous thrombolysis, early antithrombotics, 
deep vein thrombosis prophylaxis, and anticoagulation for atrial 
fibrillation) were improved (Table 2). Multivariate generalized 
estimated equations analysis revealed a 1.21-fold increase in the 
odds of receiving each performance measure from 2007 to 2012 
(Table Ⅴ in the online-only Data Supplement).
Discussion
In the current study, we observed a marked improvement in 
overall adherence to guideline-recommended performance 
measures after implementing several quality management ini-
tiatives nationwide in China. Significant improvements were 
observed in the composite score and 9 out of 13 individual 
performance measures in the overall hospitals and in 72 hos-
pitals participating in both CNSR phase 1 and 2.
Figure 2. Improvement in the stroke care quality displayed as the composite measure and the percentage of eligible patients who 
received each guideline-recommended performance metric from 2007 to 2012. DVT indicates deep vein thrombosis; IV tPA, intravenous 
tissue-type plasminogen activator; and LDL, low-density lipoprotein. *These performance measures and composite score were increased 
significantly between 2007 to 2008 and 2012 to 2013 (P<0.05).
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The improvement of individual performance measures 
and the composite score during the 5 years between 2 time 
periods was apparent even after adjusting for those previous 
reported patient’ and hospital’ variables affecting the care 
quality, such as age, sex, stroke severity, teaching status, and 
bed capacity.13,14 Potential factors for this improvement of the 
quality of care between 2007 to 2008 and 2012 to 2013 were 
inferred. First, during these 5 years, improving the quality 
of stroke care became a national priority, and several qual-
ity management initiatives of stroke care were implemented 
Table 2. Improvement of the Adherence to Performance Measures in Acute Ischemic Stroke Care and Prevention From 2007  
to 2012
All Participating Hospitals Seventy-Two Hospitals Participating in Both CNSR Phase 1 and 2
2007–2008 2012–2013 Unadjusted
Adjusted for 
Patient and 
Hospital* 
Characteristics 2007–2008 2012–2013 Unadjusted
Adjusted for 
Patient and 
Hospital* 
Characteristics
Performance 
measures
Adherence 
rate, % (N1/
N2)†
Adherence rate, 
% (N1/N2)
OR (95% CI) OR (95% CI) Adherence 
rate, % (N1/
N2)
Adherence rate, 
% (N1/N2)
OR (95% CI) OR (95% CI)
Acute performance measures‡
  IV r-tPA 2 h 14.1 
(120/1203)
18.3 
(243/1326)
1.36 
(0.85–2.16)
1.59 
(0.99–2.56)
15.1 
(102/675)
23.9 
(89/373)
1.76 
(0.93–3.32)
2.03 
(0.99–4.18)
  Early 
antithrombotics
80.3 
(9706/12 090)
84.6 
(16 149/19 093)
1.34 
(0.83–2.16)
1.17 
(0.78–1.77)
81.3 
(6169/7586)
88.7 
(4711/5311)
1.79 
(0.94–3.40)
1.55 
(0.83–3.00)
  DVT prophylaxis 59.6 
(2769/4643)
65.0 
(3556/5474)
1.25  
(0.86–1.81)
1.32 
(0.92–1.90)
61.8 
(1788/2893)
71.8 
(1176/1638)
1.56 
(0.81–3.01)
1.54 
(0.85–2.79)
  Carotid imaging 54.3 
(6339/11 677)
68.3 
(13 239/19 382)
1.81 
(1.31–2.50)
1.81  
(1.34–2.46)
55.6 
(4092/7354)
70.4 
(3809/5409)
1.89 
(1.10–3.26)
2.37 
(2.17–2.59)
  Dysphagia 
screening
36.4 
(4406/12 090)
83.3 
(15 360/18 444)
8.68  
(5.72–13.1)
7.69 
(4.99–11.89)
35.1 
(2637/7518)
79.3 
(4083/5148)
7.11 
(3.45–14.69)
8.35 
(7.59–9.20)
  Rehabilitation 
evaluation
49.3 
(5757/11 677)
58.8  
(18 939–19 382)
1.46 
(1.07–1.98)
1.42 
(1.07–1.91)
48.1 
(3534/7354)
59.8 
(3234/5409)
1.60
 (1.03–2.49)
1.75 
(1.61–1.89)
Discharge performance measures‡
  Antithrombotics 71.0 
(8285/11 677)
90.3 
(16 021/17 743)
3.80 
(2.70–5.36)
2.99
 (2.05–4.38)
71.0 
(5221/7354)
89.1 
(4598/5162)
3.33 
(1.84–6.02)
3.21
 (2.87–3.60)
  Anticoagulation 
for atrial 
fibrillation
19.7 
(221/1124)
21.0 
(332/1578)
1.08 
(0.82–1.42)
0.97 
(0.70–1.36)
18.3 
(121/662)
24.4 
(121/495)
1.44 
(0.95–2.18)
1.40 
(0.89–2.22)
  Lipid-lowering 
drug for LDL 
>100 mg/dL
42.6 
(2402/5634)
66.3 
(8475/12 791)
2.64 
(1.94–3.58)
2.72 
(2.02–3.65)
43.1 
(1584/3677)
69.0 
(2507/3633)
2.94 
(1.88–4.60)
3.05 
(2.73–3.40)
  Antihypertensive 
medication
56.4 
(4620/8196)
65.6 
(9684/14 758)
1.47  
(1.19–1.82)
1.40 
(1.16–1.69)
56.7 
(2899/5114)
70.4 
(2833/4025)
1.81 
(1.28–2.56)
1.54 
(1.40–1.70)
  Antidiabetic 
medication
62.8 
(1984/3159)
74.0 
(3977/5371)
1.68 
(1.25–2.26)
1.57 
(1.22–2.01)
61.8 
(1215/1965)
78.3 
(1177/1504)
2.22 
(1.55–3.18)
1.97 
(1.66–2.34)
  Smoking 
cessation
63.3 
(2973/4694)
85.8 
(7379/8600)
3.49 
(2.36–5.17)
3.71 
(2.68–5.14)
65.2 
(1901/2914)
92.2 
(2318/2514)
6.30 
(3.60–11.01)
5.26 
(4.39–6.32)
 Stroke education 67.3 
(7864/11 677)
97.7 
(18 936/19 382)
20.58 
(13.30–31.86)
18.78 
(12.73–27.72)
66.6 
(4900/7354)
98.0 
(5299/5409)
24.12 
(13.58–42.85)
19.66
 (16.13–24.19)
Composite 
measure§
0.63 
(0.43–0.78)
0.76 
(0.70–0.89)
1.20 
(1.16–1.25)
1.18 
(1.14–1.22)
0.63 
(0.44–0.78)
0.78 
(0.71–0.89)
1.22 
(1.16–1.28)
1.20 
(1.19–1.21)
CI indicates confidence interval; CNSR, Chinese National Stroke Registry; DVT, deep vein thrombosis; GEE, generalized estimated equations; IV, intravenous; LDL, 
low-density lipoprotein; OR, odds ratio; and r-tPA, recombinant tissue-type plasminogen activator.
*Adjusted for patient characteristics of age, race, sex, insurance schemes, previous stroke/transient ischemic attack, diabetes mellitus, hypertension, dyslipidemia, 
coronary heart disease/previous myocardial infarction, atrial fibrillation, ever smoking, and stroke severity, and hospital characteristics of times of participating in the 
registries, geographic region, teaching status, number of hospital beds, and annual stroke discharges.
†N1 indicates the number of eligible patients receiving the performance measure. N2 represents the number of patients eligible for the performance measure.
‡Change of performance measures were tested by the logistic regression model using GEE accounting for within-hospital clustering.
§Composite measure by the linear regression model using GEE accounting for within-hospital clustering.
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nationwide.4 These main interventions of the quality improve-
ment included the establishment of the National Center of 
Quality Improvement in Stroke Care, the national guidelines 
for acute treatment and secondary prevention of stroke, orga-
nizational stakeholder and opinion leader meetings, hospital 
recruitment, collaborative workshops for hospital teams, and 
hospital tool kits.4–8 These improvement tools were previously 
shown to be successful in continuously improving the qual-
ity of care in the GWTG-Stroke.12,13 The sensitivity analysis 
of the 72 hospitals participating in both of 2 phases implied 
that the sustained participation in the quality improvement 
initiatives was associated with the better gains. Additionally, 
the health insurance coverage was improved over time, which 
could be an important factor for the significant improvement 
of stroke care quality.
Despite substantial improvement in stroke care quality over 
time, gaps in adherence to the guideline-based recommenda-
tion and clinical practice still exist, even among the top 3 per-
formance measures of early antithrombotics (84.6% in 2012 
CNSR versus 97.04% in 2007 GWTG-Stroke), discharge anti-
thrombotics (90.3% in 2012 CNSR versus 98.88% in 2007 
GWTG-Stroke), and lipid-lowering drug for low-density lipo-
protein ≥100 mg/dL (66.3% in 2012 CNSR versus 88.29% 
in 2007 GWTG-Stroke).13 Furthermore, the adherences to 
intravenous tPA use (18.3%) and anticoagulation for atrial 
fibrillation (21.0%) were still lowest in 2012 in China, which 
were far down from GWTG-Stroke (72.84% and 98.39% 
separately) in 2007. The potential reasons for the low imple-
mentation rate of intravenous tPA included the high cost of the 
tPA, the low health coverage rate, concern for safety of using 
intravenous tPA in China.3 Stroke center certification has been 
proven to increase the use of thrombolytic therapy.15 However, 
it was not developed in China. As for the prescription of war-
farin, because of the narrow therapeutic margin and drug or 
food interactions of warfarin, frequent international normal-
ized ratio testing and dose adjustments are required. In China, 
insufficiency of a comprehensive community health service 
makes frequent INR testing difficult. Additionally, physicians 
are concerned about the safety of using warfarin.16 New oral 
anticoagulants are an alternative for warfarin and recom-
mended by guidelines without monitoring INR and increasing 
the risk of hemorrhage.17
Increased compliance with acute stroke care and second-
ary prevention guideline-recommended performance metrics 
is associated with favorable outcomes.18 Patients in the CNSR 
phase 2 had better functional outcome at discharge than those 
in CNRS phase 1. The median length of stay was reduced by 
1 day. Meanwhile, the in-hospital mortality was decreased 
from 4.1% to 1.1%, which was consistent with the findings of 
the previous study among ischemic stroke patients in China 
from 2.48% to 1.47% from 2007 to 2010.19 Patients in the 
2012 to 2013 data set were younger and had lower National 
Institutes of Health Stroke Scale scores, which may decrease 
the risk of in-hospital death.20 Second, these improvements of 
in-hospital outcomes may reflect the quality improvement of 
in-hospital stroke care and potentially contribute to decreases 
in the cost of care.21 Additionally, several confounding factors 
related with in-hospital mortality should be considered, such 
as that some families of patients who have severe strokes may 
request to die at home based on previous wishes in China, the 
improvement in public awareness resulting in more patients 
arrived early and treated early, or even changes in length of 
stay. If stroke patients continue to comply with the preven-
tion measures after discharge, a substantial decline in stroke 
recurrence may also be predicted according to clinical guide-
lines.4,6,21 Additionally, given the enormous number of stroke 
inpatients each year in China, even superficially modestly 
increased odds of evidence-based health care will convert into 
enormously more healthcare opportunities to be implemented. 
These sustained improvements of the quality of care could 
translate into enormous cost savings in the long term.
Meanwhile, there exist several limitations in this study. 
First, some of the participating hospitals in 2012 had no 
baseline data of the quality of care in 2007. The possibility 
that hospitals in 2012 were simply better all along existed. 
To reduce this bias, the comparable basic structure char-
acteristics of hospitals between the 2 phases were consid-
ered when we selected the potential participating sites in 
2012. Improvements in stroke care quality after adjusting 
for patient- and hospital-level variables were still observed 
among those 72 returning hospitals, suggesting that the 
improvements are substantial. The potential reasons that part 
of the hospitals involved in CNSR phase 1 did not continue 
through phase 2 included that these quality improvement ini-
tiatives required hospitals to invest enough human, material, 
and funding resources. Second, observed differences of stroke 
care quality might also reflect the secular trend besides these 
stroke quality management initiatives themselves. Because 
stroke care quality was not consecutively recorded among the 
participating hospitals from 2007 to 2012, this change with 
time was not analyzed independently as was the case for the 
GWTG-Stroke.13 The causal relationship between these ini-
tiatives and the improvement of the quality of care could not 
be established. To prevent these types of bias, a cluster-ran-
domized trial of a targeted multifaceted intervention to bridge 
the evidence-based gap in the management of acute ischemic 
stroke in China is ongoing.22 Additionally, the healthcare 
delivery varies widely in China, and hospitals voluntarily 
participating in the CNSRs and network may be interested in 
the stroke care quality improvement, so the observed findings 
may not represent the quality of care nationwide.
As the aging process of China’s population structure is 
accelerating, the burden of stroke becomes increasingly 
heavy. Although improvement of stroke care quality is 
observed in this study, significant opportunities exist for fur-
ther improvement. Continuous quality improvement of stroke 
care should be developed as a sustained priority in China. 
Efforts that increase the input of the financial and human 
resources to the stroke care, implement targeted initiatives 
for improvement of stroke care across the country, develop 
certification of stroke center, and strengthen physician and 
public knowledge may contribute to further improvements of 
the quality of care in China.
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